Search This Blog

Friday, September 14, 2018

New Apple Watch doesn’t have the feature most consumers want


Apple Inc. has introduced a new Apple Watch, but jazzed-up health features in the smartwatch may not be enough for consumers who don’t seem willing to pay up for the priciest Apple wearable.
That’s according to analysts at Counterpoint Research, who wrote late last month that consumers were overwhelmingly opting for the cheaper Apple Watch Series 1 rather than the Series 3 device, which was then the newest.

Apple AAPL, -1.14%  has since killed off the Series 1 and launched a new Series 4 model, which boasts a larger screen, better cellular connectivity, a number of new health features, and the ability to view more on the home screen. The new cellular model starts at $499, while the new GPS-only model begins at $399.

Apple will continue to sell the Series 3 version for a new, lower starting price of $279, which may be an attractive option for people who want an Apple Watch but don’t see the bigger screen or enhanced health functions as worthy of a steeper price.
“We continue to expect the lowest price option will account for the bulk of Watch volume on a global basis,” Counterpoint’s research director Pete Richardson told MarketWatch via email.

In his view, the company is trying to position the watch as a more health-oriented device, given that health and wellness uses have been among the more attractive aspects of smartwatches. Heart-focused tools, as well as a feature that detects falls, could conceivably make Apple’s watch more appealing for older generations, but Richardson questions how many older people are going to buy an expensive smartwatch to monitor their heart—and then buy a pricey new iPhone to make it all work.
Meanwhile, he expects that battery life will remain an issue for potential Watch buyers, given that the Series 4, like the Series 3, won’t even last a single day.
“This will limit its usefulness for things like sleep tracking or monitoring heart rhythms while sleeping, often a period when cardiac issues need to be most closely monitored,” he said.

The Apple Watch is, of course, priced significantly lower than the iPhone, but it serves as a way for the company to get users even more hooked into the Apple ecosystem. Apple doesn’t break out sales or unit data for its wearables, but a continued preference for lower-priced watches would pressure watch average selling prices.
Others were more upbeat about the new Watch developments. Baird analyst William Power wrote Thursday that the Series 4 got a “strong upgrade” that “upstage[d]” the iPhone. He rates Apple’s stock at outperform and upped his price target to $235 from $230.
Bernstein’s Toni Sacconaghi was more effusive, writing positively of the device’s new health features centered on atrial fibrillation and electrocardiograms.
“We were impressed by the incremental new features of the Watch…and see the announcement as supportive of our thesis that Apple Watch could eventually be an indispensable health monitoring device capable of saving lives,” wrote Sacconaghi, who rates the stock at market perform with a price target of $200. He ultimately sees the Apple Watch becoming a device that more health players are willing to subsidize.

Apple’s Series 4 announcement weighed on shares of Fitbit Inc. FIT, -2.30% which dropped 7% in Wednesday’s session before rebounding 2% on Thursday. Garmin Ltd.’s GRMN, +0.16%  stock was nearly flat Wednesday and rose about 1% in Thursday’s session.
Apple shares closed down 1.4% Friday, though they’re up 41% over the past 12 months. The Dow Jones Industrial Average DJIA, +0.03% of which Apple is a component, has gained 18% in that time.

For Canada pot investors, coming to US is a ‘crapshoot’ that can end in lifetime ban


Visiting the U.S. is a “crapshoot” that could lead to a lifetime ban for foreign nationals who are invested or work in the Canadian marijuana industry, which could hurt the booming sector, immigration lawyers said Friday.
Todd Owen — a senior officer with U.S. Customs and Border Protection, or CBP, overseeing border operations — told Politico in an interview published Thursdaythat border agents would still seek to permanently ban any foreign visitor who admits to working or investing in the cannabis industry, or admits to have taken the drug, even after recreational marijuana use becomes legal in Canada on Oct. 17.
MarketWatch confirmed that stance in an email exchange with a CBP spokeswoman, who said investors could face a permanent ban from entering the U.S.
“Although medical and recreational marijuana may be legal in some U.S. states and Canada, the sale, possession, production and distribution of marijuana or the facilitation of the aforementioned remain illegal under U.S. federal law,” spokeswoman Stephanie Malin said in a statement.
In a follow-up exchange, Malin confirmed that investing in publicly traded marijuana companies, including those traded legally on U.S. exchanges, is considered “facilitation” of illicit drug trade under CBP policy.
“That’s the first [time] I’ve actually heard them say a Canadian-only enterprise is an illegal enterprise for U.S. entry purposes,” said Scott Railton, a lawyer at Cascadia Cross-Border Law in Bellingham, Wash.

Railton explained that, once recreational marijuana is legal in Canada, a Canadian business that provides marijuana only within that country, not in the U.S., would not be involved in an illicit business.
“I really question how they can deny someone admissibility on the illegal-trafficking grounds when the industry is not illicit in a foreign country,” Railton said. “That’s a novel interpretation of that law that is an expansive one [and] that will require a judge to look at.”
Railton said he has advised Canadians who were interested in investing in Canadian pot companies and were concerned about their ability to travel to the U.S. and sees the potential for potential investors to avoid the sector because of the risk of a travel ban.
“There is a potential chilling effect on actual investment if the agency is taking that position,” Railton said. “It would have an impact. There are Canadian investors who would steer clear.”
Three Canadian pure-play marijuana companies are publicly listed on the major U.S. exchanges: Tilray Inc. TLRY, -8.94% , Canopy Growth Corp. CGC, +7.08% and Cronos Group Inc. CRON, +2.67% . Their share prices have posted rapid gains as Canadian legalization approaches.
There are many more Canadian pot companies listed in that country, such as Aurora Cannabis Inc. ACB, +2.89% and Valens GroWorks Corp.MYMSF, +18.58% , and they have also been hot investments. The Horizons Marijuana Life Sciences Index ETF HMMJ, +3.76% ,which tracks more than 20 cannabis companies in North America and trades on the Toronto Stock Exchange, has risen more than 14% this year, beating the U.S. benchmark S&P 500 index’sSPX, +0.03% 8.6% gain.
American citizens and dual citizens of the U.S. and Canada are free from risk, as the policy pertains only to citizens of other countries seeking to enter the U.S. For foreign nationals with investments in the cannabis business, however, visiting the border is a “crapshoot,” according to lawyer Terry Preshaw.
”Even though marijuana has been or is about to be legalized on both sides of the border here in Washington state, there is this thin line called the border where it is still a crime,” said Preshaw, who is licensed to practice law in both countries.

Lawyers who spoke with MarketWatch said guards at the border have the freedom to ask any questions they deem fit.
”They have really absolute power, in a nutshell,” Preshaw said.
“CBP officers are thoroughly trained on admissibility factors and the Immigration and Nationality Act, which broadly governs the admissibility of travelers into the United States,” the agency’s spokeswoman said in her official statement. “Determinations about admissibility and whether any regulatory or criminal enforcement is appropriate are made by a CBP officer based on the facts and circumstances known to the officer at the time.”
The question is how often foreign visitors are asked about their investments. Investors or workers who are prominently mentioned as such online could be more likely to be questioned about potential investments or employment in the cannabis industry, lawyers said.
“If that person fits a demographic that the officer thinks they might be a user or an investor and anything in between, the officer has the power to ask the right questions,” Preshaw added, while cautioning that “unless someone drops a clue and an astute border officer picks up on the clue, it doesn’t seem like a question that will be asked routinely.”
MarketWatch on Friday spoke with a Canadian citizen who was banned from visiting the U.S. after admitting to an investment in a company tangentially related to medicinal marijuana. The person requested not to be named in this report, but the story was confirmed by the person’s lawyer, who is not named in this article.
The person reported traveling across the border in April for lunch with an executive at a company in the U.S., and being stopped for additional questioning. Eventually, in an ordeal that, according to the person’s account, lasted six to seven hours and included car and phone inspections, being handcuffed and being accused of being a felon and a drug dealer, the person admitted that the company had a subsidiary that was studying medicinal marijuana, though that was not the core business in which the person had invested.
Still, the person was banned from the U.S. for life at the end of “one of the worst experiences of my life.”
“You’re interrogated, intimidated, banned for life, no information, no one to talk to, no resources to how to resolve it,” the person said.
Those who are banned can apply for a waiver to visit the U.S., but this person has no interest in doing so. “I really want nothing to do with the U.S., and I certainly don’t want to support the country in any way.”
That is not the only story of its kind. Vancouver venture capitalist Sam Znaimer told CTV News that he was quizzed about his investments when attempting to cross into the U.S. in May, and was hit with a lifetime ban after admitting to investments in U.S. cannabis companies. Znaimer, who did not respond to an email Friday, said in July that border guards did not ask about his personal consumption of the drug, only his investments.
“I believe that was because they wanted to send a message to Canadians that it has not only to do with your personal behavior, but whether in any way you have invested in these companies,” he told CTV.

In another case, workers, including the chief executive, at agricultural-equipment maker Keirton Inc. were hit with a lifetime ban in April after attempting to enter the U.S. to discuss designing equipment for cannabis production with an American company. The company had not yet even begun to design the machine, yet CEO Jay Evans told the Star that border guards explained that he and his colleagues were “drug traffickers” according to U.S. law.
Keirton officials declined to comment further, telling MarketWatch: “We have already stated the facts in a previous interview, and anything else would just be opinion.”
The immigration lawyers who spoke with MarketWatch cautioned that lying to the CBP about drug use or investments could still lead to a lifetime ban for misrepresentation. Preshaw said the best approach, if asked a question that could lead to a ban, is to turn right back around.
“Say this: ‘I respectfully request to withdraw my application at this time,’ ” she said. “Do it before you are refused and abort the trip; it’s not worth being refused entry for life.”
Recreational use of marijuana is now legal for adults 21 and older in all of the Pacific Coast states — Washington, Oregon and California — as well as Nevada, Colorado, Alaska, Vermont, Massachusetts, Maine and Washington, D.C. Dozens of other states permit medical marijuana.

Lucid dreaming: Controlling the stories of sleep


Have you ever started dreaming and suddenly realized that you were in a dream? Have you ever managed to gain control over your dream narrative? If your answer to these is “yes,” you’ve experienced what is called lucid dreaming.
Lucid dreaming has recently been popularized by movies such as Inception.
The movie features impressive dream artisans who are able not just to control the shape and content of their own dreams, but also those of others.
Such feats of dream manipulation may not seem possible to the same extent in our real lives, but they are not altogether absent.
In fact, certain people are able to experience something referred to as lucid dreaming, and some of them are able to control some of the elements of their nightly dreams.
In his much-cited poem, Edgar Allan Poe once wrote, “All that we see or seem/Is but a dream within a dream.”
Whether or not he is right is a matter for philosophers to debate, but the boundary between dream and reality is something that lucid dreaming seems to explore.
In this Spotlight, we look at what qualifies as lucid dreaming, whether these experiences can have any practical applications, and how one might be able to become a lucid dreamer.

What is lucid dreaming?

Typically, when we dream, we are not conscious that the dream is not real. As a character from the movie Inception quite aptly puts it, “Well, dreams, they feel real while we’re in them right? It’s only when we wake up then we realize that something was actually strange.”
However, some of us are able to enter a dream and be fully aware of the fact that we are actually dreaming.
“A lucid dream is defined as a dream during which dreamers, while dreaming, are aware they are dreaming,” specialists explain.
The very first record of lucid dreaming appears to feature in the treatise On Dreams by the Ancient Greek philosopher Aristotle. In it, he describes an instance of self-awareness during a dream state.
“[If] the sleeper perceives that he is asleep, and is conscious of the sleeping state during which the perception comes before his mind, it presents itself still, but something within him speaks to this effect: ‘The image of Koriskos presents itself, but the real Koriskos is not present,'” he wrote.
It is unclear how many people actually experience lucid dreaming, though certain studies have tried to gather information regarding its prevalence; and it seems that this phenomenon may be quite common.
For instance, a study conducted in Brazil surveyed 3,427 participants with the median age of 25. The results of the survey indicated that 77 percent of the respondents had experienced lucid dreaming at least once.

When does it happen, and what is it like?

Like most dreams, lucid dreaming will typically occur during rapid eye movement (REM) sleep. For some people, it occurs spontaneously. However, others train themselves to start dreaming lucidly, or to become better at it.
As one experienced lucid dreamer told Medical News Today:
[M]y lucid dreaming […] occurs when I’m waking up, or sometimes if I’ve woken up briefly and I’m going back to sleep. Nowadays I can pretty much do it on a whim, as long as I’m in that half-asleep half-awake process.”
The degree to which a person can influence their dream if they are lucid while dreaming also varies to a great extent. Some people may simply wake up immediately upon realizing that they had been dreaming.
Other people may be able to influence their own actions within the dream, or parts of the dream itself. The lucid dreamer who spoke to MNT told us that she was able to manipulate the dream narrative in order to create a pleasant experience for herself.
“Usually I can control the narrative in the dream, so for example if I’m unhappy with the way things are going in the dream, I can change it,” she explained.

What are its applications?

Lucid dreaming is certainly an attractive and fascinating prospect — being able to explore our own inner worlds with full awareness that we are in a dream state is intriguing and has an almost magical flavor about it.
However, can lucid dreaming have any practical applications?
Dr. Denholm Aspy, at the University of Adelaide in Australia, is a researcher who specializes in lucid dreaming.
He explained for MNT that this experience can actually be therapeutic.
Its main application, Dr. Aspy said, is to address nightmares — especially recurring nightmares, which may affect a person’s quality of life.
The practice of learning to lucid dream in order to stop nightmares from occurring or reoccurring, he explained, is called “lucid dreaming therapy.”
“If you can help someone who’s having nightmares to become lucid during that nightmare,” he explained to us, “then that gives them the ability to exert control over themselves or over the nightmare itself.”
[L]et’s say you’re being attacked by someone in a nightmare. You could try to talk to the attacker. You could ask them ‘why are you appearing in my dreams?’ or ‘what do you need to resolve this conflict with me?'”
Dr. Denholm Aspy
“Some people,” he added, “take on superpowers or special abilities, [so] they can fight back against the attacker. And then you can also try to escape, so things like flying away, or even doing techniques to deliberately wake up from the nightmare.”
Lucid dreaming also has the potential to help people with phobias, such as fear of flying or animal phobias including arachnophobia (the fear of spiders).
“If a person has a particular phobia, then their lucid dream environment […] provides an interesting opportunity to do things like exposure therapy, where you gradually expose yourself to the thing you’re afraid of, in an attempt to gradually overcome that fear,” Dr. Aspy said.
This is possible, he said, because dream environments can provide a realistic enough experience without it actually feeling unsafe. During lucid dreaming, the individual knows that they are not in the real world, so they may safely explore their fears without actually feeling threatened.

‘Lucid dreaming is a kind of creative activity’

At the same time, lucid dreaming is also attractive as an unusual means of entertainment — kind of like the immersive experience of virtual reality.
An experienced lucid dreamer might be able to “go on an adventure” and interact with people and things in a way that they may not be able to do in real life.
The lucid dreamer who spoke to MNT said that she thinks of the experience as something akin to storytelling, which makes her feel happier upon waking up:
Lucid dreaming for me is a kind of creative activity — I get to explore what my dreams are telling me a little bit versus what my conscious mind wants. It’s not got much use apart from just being interesting and it makes me happy usually […] I tend to wake up quite content.”
“I do lucid dreaming for fun,” she went on to say. “I enjoy it, and as someone who enjoys storytelling it’s a similar experience to writing a story or playing a video game. You get immersed in a narrative that involves you in some way.”

Techniques for lucid dreaming

There are many techniques that people who want to try and achieve lucid dreaming — or who want to perfect their lucid dreaming experiences — employ.
study conducted by Dr. Aspy and colleagues last year tested the efficacy of three common techniques.
The first is known as “reality testing.” This might involve verifying whether you are dreaming both in real life and during a dream.
For instance, throughout the day, a person may want to ask themselves “am I dreaming right now?” as they pinch themselves, or try to make their hand pass through a solid wall.
This technique relies on intention. In reality the pinch will hurt, but in a dream it will not. In real life the wall will remain solid and impenetrable, while in a dream the hand will easily pass through.
Another “reality check” is rereading a line of text. In reality, if we read the text on a poster, for instance, it will stay the same when we reread it. In a dream, however, the text will constantly shift.
Conducting these experiments repeatedly throughout the day may make it easier to remember to conduct them during a dream state, thus allowing the dreamer to gain awareness of the dream.
Another technique is “waking back to bed,” and it requires setting an alarm to wake up the sleeper after about 5 or 6 hours of going to sleep.
Once awake, the person should aim to remain awake for a while, before going back to bed. This technique is supposed to immerse the sleeper immediately into REM, the phase of sleep during which they are more likely to experience a lucid dream.
Finally, lucid dreaming may eventually occur through “mnemonic induction.” Once more, this is a technique that requires intent and lots of practice.
With mnemonic induction, a person must repeat to themselves, just before going to bed, a phrase such as “tonight, I will notice that I am dreaming,” so as to “program” themselves to achieve in-dream lucidity.

Dream journals and meditation

It also appears that those who find it easier to lucid dream do not have much trouble recalling their dreams on a regular basis.
“When it comes to lucid dreaming, the strongest predictor of whether you have lucid dreams or not is how good you are at remembering your ordinary dreams,” Dr. Aspy explained.
Therefore, some people who are interested in exploring their dreams with full awareness may find it useful to keep a dream journal in which they record the dreams that they have each night in as much detail as possible.
The lucid dreamer that we interviewed corroborated this idea by noting that, for a long time, she used to enjoy writing down her dreams upon waking up.
Another practice that may aid lucid dreaming is meditation, or mindfulness, as it “trains” people to become more aware of themselves and their surroundings, in general.
“A lot of people are interested in meditation and mindfulness as a way to have lucid dreams,” Dr. Aspy mentioned, explaining, “The idea there is that if you’re more aware during the day, you’re more likely to notice that you’re dreaming while you’re asleep.”

Concerns and risks

One concern that people express about engaging in lucid dreaming, if they are able to achieve it, is that they may get “stuck” in a dream and find it more difficult to wake up.
However, Dr. Aspy explained to MNT that this is not a worrying risk; normally, an individual is only able to sleep — and dream — for a set amount of time every night, so it is unlikely that anyone would get “stuck” sleeping.
He told us, “The main reason for that is — pretty much no matter what you do you are only going to, on average, only have a certain amount of sleep and dreaming every night. There are some things that you can do to increase it a little bit, but you can’t really sustain that for very long.”
Another concern is that engaging in lucid dreaming requires focus and effort, which might mean that the sleeper does not get enough rest.
However, Dr. Aspy again reassured us, noting that the lucid dreamers with whom he has worked in the past have not reported more tiredness or poorer sleep quality as a result of lucid dreaming.
At the same time, in speaking to us, he also issued a warning to aspiring lucid dreamers:
I generally recommend that people don’t pursue lucid dreaming if they have certain mental health problems.”
One example is schizophrenia, which may cause people to be unable to distinguish between some of their thoughts or fears and real-life events. In some cases, Dr. Aspy noted, lucid dreaming may actually exacerbate the condition.
Lucid dreaming may be a fascinating, helpful, or pleasant experience, but you should still consider why you are interested in achieving it, and what you expect to get from it, before trying to experiment with dream states.

Gene therapy shown to remove core component of Parkinson’s disease


Gene therapy shown to remove core component of Parkinson's disease
Photomicrograph of regions of substantia nigra in a Parkinson’s patient showing Lewy bodies and Lewy neurites in various magnifications. Top panels show a 60-times magnification of the alpha synuclein intraneuronal inclusions aggregated to …more
An international team led by Rush researcher Jeffrey Kordower, Ph.D., has moved a step closer to developing a treatment to clear brain cells of a protein that is an integral cause of Parkinson’s disease. The team published the findings of their study in the Aug. 22 issue of Nature Parkinson’s Disease.
Parkinson’s disease is a chronic, progressive movement disorder that affects the body’s ability to control movement. The condition is a result of damage to that produce dopamine, a chemical that relays messages to the parts of the brain that control movement, resulting in trembling, stiffness, slow movement and poor balance and coordination.
Working with rats induced with a simulation of Parkinson’s disease, Kordower’s team showed that a genetically engineered fragment of an antibody—called a nanobody—cleared away toxic clumps of the protein  after the team injected the nanobody into the rats’ brains.
The hope is that once this therapy is introduced, it will continue to keep brain cells clear of the alpha-synuclein for the rest of the person’s life, said Kordower, a professor in Rush Medical College’s Department of Neurological Sciences, where he also is director of the Section of Neurobiology.
Fixing cells from within
Alpha-synuclein, abbreviated as α-syn, occurs naturally in the brain and elsewhere in the body. In neurological disorders, however, the protein clusters in misfolded (abnormally clumped together) and disordered forms. In Parkinson’s disease—known as PD for short—malformed α-syn accumulates in distinctive formations called Lewy bodies, which is considered an integral part of PD.
“We’re looking for ways to reduce alpha-synuclein levels, accumulation and toxicity resulting from the spread of alpha-synuclein around the nervous system,” Kordower said.
The treatment his team is testing is part of a rapidly evolving approach that deploys therapeutic nanobodies to invade cells as part of genetically-altered viruses. In this study, once inside the cell, the nanobody appears to have stopped the clumping of the dysfunctional α-syn that leads to a loss of nerve cells and, eventually, full-blown PD. Stopping the clumping should prevent the progression of the disease.
This study is the first to use nanobodies for PD. Some previous research has shown promise with clearing α-syn in areas outside the cells, but Kordower believes an intracellular approach could be even more effective, because the amount of α-syn within cells is more plentiful than the amount outside them. “If you reduce intracellular levels, chances are that the a-synuclein won’t get extracellular, so it won’t spread,” Kordower elaborated.
Gene therapy shown to remove core component of Parkinson's disease
Letting PESTs inside
His team created an “overexpression” (overabundance) of α-syn in the test rats’ brains. They then tested two types of the gene therapy, each on a different group of rats, and used saline in a , to see if the nanobodies could clear away the clutter inside those cells. The nanobodies were custom-made for the study by the University of North Carolina Vector Core.
One of the treatments, VH14*PEST, clearly worked best. It improved dopamine levels and reduced motor-function symptoms significantly better than the saline given the control group. VH14*PEST measurably improved the symptoms by one measure, the stepping test, and somewhat by another measure called the cylinder test.
VH14*PEST accomplished these results by reducing the levels of an amino acid in α-syn called Serine-129 that had undergone a chemical reaction called phosphorylation (the addition of a phosphate). Amino acids are the building blocks of proteins, and Serine-129 is a normal component of α-syn, but phosphorylated Serine-129 causes the deformities in α-syn that are seen in PD.
“The decrease in serine 129 phospho synuclein demonstrates the success of the nanobodies in reducing pathological alpha synuclein in the brain,” Kordower said.
The second nanobody the team tried, NbSyn87*PEST, was effective, but less so overall, and had side effects like increased inflammation. PEST refers to a sequence of the  proline, aspartate or glutamate, serine and threonine, which targets proteasomes – combinations of proteins that work to break down unneeded or damaged proteins. This PEST sequence has been found to be an effective intervention against disordered proteins such as the excessive α-syn found in Parkinson’s.
‘Humanizing’ a PEST
Given the promising results of the VH14*PEST treatment, Kordower and his team plan to pursue it further. First, though, the group has to fully “humanize” the compound it used in the rat model. That is, they have to make it safe for people.
“Then we have to repeat these studies, in rats, with the humanized version to make sure it is as effective as the ones we’ve been testing,” which were compatible with a rodent’s physiology, Kodower explained. Only then can the team consider using the therapy in clinical trials in humans.
Down the road, this nanobody treatment could have implications for other parts of the brain as well, including the cortex, where misfolded α-syn may cause dementia, Kordower added.
More information: Diptaman Chatterjee et al. Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model, npj Parkinson’s Disease (2018). DOI: 10.1038/s41531-018-0062-4

Antioxidant NAC found to be effective in treating mice with osteoarthritis


Antioxidant found to be effective in treating mice with osteoarthritis
Antioxidant treatment with NAC prevented osteoarthritis and mitigated cartilage damage in the knee joints of mice deficient in Anp32 (right column). Credit: F.M.F. Cornelis et al., Science Translational Medicine (2018)
A team of researchers in Belgium and the Netherlands has found that feeding a common antioxidant to test mice was effective in treating osteoarthritis. In their paper published in Science Translational Medicine, the group outlines their study of the cause of the most prevalent joint disorder in the world and what they found.
Osteoarthritis is a degenerative disease that results in loss of joint cartilage and bone. It is most common in  and results in pain and disability for millions of people the world over. There is currently no cure and treatment is limited to drugs that reduce associated inflammation. In this new effort, the researchers have made inroads regarding understanding how the disease comes about and have found a therapy for it that proved effective in .
The work involved studying people experiencing . They studied tissue samples and found decreased levels of the protein ANP32A. So they investigated the role it plays in the body—genetic profiling showed that the protein was involved in monitoring levels of an enzyme called AMT. Under normal circumstances, levels were adjusted to respond to  in cells in joint cartilage—low levels led to increased stress. This finding suggested that boosting ANP32A levels artificially might prevent the progression of the disease. Intrigued by their findings, they administered an antioxidant called N-acetyl-cysteine (NAC) to test mice with osteoarthritis—they had been bred in a way that made them unable to make ANP32A. NAC is currently used to improve lung function in people with emphysema, cystic fibrosis, tuberculosis, bronchitis and other lung ailments. The researchers report that adding it to the mice’s water led to reduced loss of bone and cartilage compared to untreated mice.
The researchers note that because of differences in physiology, it is unlikely that giving NAC to people with osteoarthritis would help much—they plan instead to look for ways to induce increased production of ANP32A in patients, thereby preventing the  from taking its toll.
More information: Frederique M. F. Cornelis et al. ANP32A regulates ATM expression and prevents oxidative stress in cartilage, brain, and bone, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aar8426

Teva announces FDA OK of AJOVYTM injection for migraine prevention

Teva announced that the U.S. FDA has approved AJOVYTM injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly and monthly dosing options.
https://thefly.com/landingPageNews.php?id=2790937

#OpenAPS DIY Artificial Pancreas Tech Use Implies Improved A1C, Quality of Life


Patient-driven innovation in diabetes management has resulted in a group of people with type 1 diabetes who choose to build and share knowledge around a do-it-yourself (DIY) open source artificial pancreas systems (OpenAPS). The purpose of this study was to examine Twitter data to understand how patients, caregivers, and care partners perceive OpenAPS, the personal and emotional ramifications of using OpenAPS, and the influence of OpenAPS on daily life.
Qualitative netnography was used to analyze #OpenAPS on Twitter over a two-year period.
There were 328 patients, caregivers, and care partners who generated 3347 tweets. One overarching theme, OpenAPS changes lives, and five subthemes emerged from the data: (1) OpenAPS use suggests self-reported A1C and glucose variability improvement, (2) OpenAPS improves sense of diabetes burden and quality of life, (3) OpenAPS is perceived as safe, (4) patient/caregiver–provider interaction related to OpenAPS, and (5) technology adaptation for user needs.
As users of a patient-driven technology, OpenAPS users are self-reporting improved A1C, day-to-day glucose levels, and quality of life. Safety features important to individuals with diabetes are perceived to be embedded into OpenAPS technology. Twitter analysis provides insight on a patient population driving an innovative solution to improve their quality of diabetes care.